 |
|
|
| |
A MULTICENTER STUDY OF PROTEASE INHIBITOR-TRIPLE THERAPY IN HCV-INFECTED LIVER TRANSPLANT RECIPIENTS: REPORT FROM THE CRUSH-C GROUP
|
| |
| |
Reported by Jules Levin
EASL 2013 April 24-28 Amsterdam
E.C. Verna1*, J.R. Burton2, J.G. O'Leary3, J.C. Lai4, V. Saxena4, J.L. Dodge4, G.T. Everson2, J.F. Trotter3, R.T. Stravitz5, R.S. Brown, Jr.1, N.A. Terrault4, CRUSH-C
1Columbia University College of Physicians and Surgeons, New York, NY, 2University of Colorado, Denver, CO, 3Baylor University Medical Center, Dallas, TX, 4University of California San Francisco, San Francisco, CA, 5Virginia Commonwealth University, Richmond, VA, USA
EASL: End Of Treatment Response After Protease Inhibitor-based Therapy For Hepatitis C Recurrence After Liver Transplantation: A Multicentric European Experience - (05/03/13)
EASL: PHARMACOKINETIC INTERACTIONS BETWEEN THE HCV PROTEASE INHIBITOR BOCEPREVIR AND SIROLIMUS IN HEALTHY SUBJECTS - (05/06/13)
|
| |
|
|
|
|
|
